ClinicalTrials.gg
RecruitingNCT04387812Updated Mar 10, 2023

Evaluation of the Frequency and Severity of Sleep Abnormalities in Patients With Parkinson's Disease

An interventional study of Xtrodes home PSG system in Parkinson Disease, GBA Gene Mutation and Leucine-rich Repeat Kinase 2 (LRRK2) Gene Mutation, sponsored by Tel-Aviv Sourasky Medical Center. Recruiting at 1 site in Israel. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-10.

Sponsored by Tel-Aviv Sourasky Medical Center · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started Jun 2020; still recruiting 6 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Not applicable
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Parkinson Disease by Tel-Aviv Sourasky Medical Center — 4 open to participants now, 4 under way, none of them phase 3. Parkinson Disease · Tel-Aviv Sourasky Medical Center.

Planned enrollment
2nd of 14
240 · median 50
Started
2020
the only one that year
No phase
13 of 24
3 open now
Registered
20th of 24
by date

Among the 24 studies in Parkinson Disease by Tel-Aviv Sourasky Medical Center, this one is the 2nd largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2020, is one of 13 with no phase, and was the 20th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

4 of the 24 studies in Parkinson Disease by Tel-Aviv Sourasky Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Parkinson Disease by Tel-Aviv Sourasky Medical Center, or all of them as a file.
02

Study summary

Sleep disturbances are one of the most common non-motor symptoms in PD, with an estimated prevalence as high as 40-90%. Sleep disturbances (particularly sleep duration, sleep fragmentation, Rapid Eye Movement (REM) sleep behavior disorder and sleep-disordered breathing) have been associated with an increased risk of neurodegeneration and are an independent risk for cognitive decline and dementia in PD.

Although much is currently unknown about sleep changes in PD, sleep-related symptoms are increasingly recognized as a major contributor to disease burden and reduced quality of life among people with PD. The "gold standard" evaluation of nocturnal sleep is polysomnographic monitoring (PSG).

This study proposes to use novel wireless skin electrodes and wearable sensors to provide a "home PSG test" incorporating several physiologic recordings, over multiple nights in the person's home, enabling the objective evaluation of night-to-night fluctuations.

Read the detailed description

Background Sleep disturbances are one of the most common non-motor symptoms in PD, with an estimated prevalence as high as 40-90%. Sleep disturbances (particularly sleep duration, sleep fragmentation, Rapid Eye Movement (REM) sleep behaviour disorder and sleep-disordered breathing) have been associated with an increased risk of neurodegeneration and are an independent risk for cognitive decline and dementia in PD. The etiology of impaired sleep and alertness in PD is multifactorial and may be due to the interactions between internal and external factors such as primary sleep disorders, primary neurodegeneration, medication side effects, environmental conditions and genetic factors (either associated with sleep or associated with disease phenotype). Each can contribute to sleep disturbances alone or as modifiers, resulting in variability of presentation and symptoms, affecting both the diagnosis, and the treatment of these disorders. Although much is currently unknown about sleep changes in PD, sleep-related symptoms are increasingly recognized as a major contributor to disease burden and reduced quality of life among people with PD.

The "gold standard" evaluation of nocturnal sleep is polysomnographic monitoring (PSG). PSG consists of measuring neural function, eye movements, muscle activity, respiratory status and electrocardiography activity while the person sleeps over-night in a laboratory setting. This assessment allows for quantification of the different sleep stages during non-REM and REM, evaluation of their distribution over the course of the night, and the identification of impairments in each of these stages. However, PSG is time, cost and labor-intensive, may not reflect the typical behavior of the person due to the unfamiliar environment and irregular sleeping conditions, and more importantly, only provides information on one night of sleep.

In recent years, there is heightened interest in home-based sleep monitoring via wearable sensors to address these shortcomings. Body-fixed electrophysiological sensors can objectively quantify sleep quality, generating a detailed map of the person's sleeping pattern and nocturnal movements. They are relatively inexpensive enabling wide-spread use.

This study proposes to use novel wireless skin electrodes and wearable sensors to provide a "home PSG test" incorporating several physiologic recordings, over multiple nights in the person's home, enabling the objective evaluation of night-to-night fluctuations. By applying these novel tools to the study of people with PD as well as controls and subjects at risk for developing PD, the results of this study will open the door for using a new method for assessment of prodromal signs and disease progression.

Study objective

Main objective is to use the combined wearable system described above to evaluate sleep disturbances across a wide spectrum of PD disease severity: from the prodromal phase with individuals at risk to mild and advanced PD:

  1. To investigate changes in sleep architecture and unique patterns of sleep in individuals at risk for developing PD (patients with confirmed RBD and carriers of mutations in the LRRK2 and GBA genes) that can help to better identify increased risk of disease.
  2. To assess the frequency, severity and types of sleep disturbances in patients with PD across the disease spectrum.
  3. To identify classifiers of sleep measures indicative of disease characteristics, severity and progression.
  4. To assess the association between sleep disorders, disease severity, autonomic, motor, cognitive functions, and medication.

Subjects will be recruited and evaluated from the Laboratory for Early Markers of Neurodegeneration (LEMON) at the Neurological Institute at the Tel Aviv Medical Centre (TLVMC). All subjects will provide informed written consent as approved by each TLVMC's ethical committee and in accordance with the Helsinki agreement prior to participation.The 'Genetics in Parkinson's Study' registry will be used for initial recruitment of participants. This is a registry of participants (patients and family members who have undergone genetic testing in our lab previously and have agreed to allow contact for future studies (under Helsinki agreement of 05-069 and 07-0381). PD patients will be approached by their physician to provide consent to participate in the sleep study. Asymptomatic participants will be recruited from the registry or from public advertisements and word to mouth approach. Those willing to participate will be invited to LEMON for an assessment meeting. Subjects will be provided with a detailed explanation of the study protocol before being asked to sign the consent form.

Procedures:

After signing an informed written consent, participants will be asked about their current and medical history, sleep habits, dietary, alcohol and caffeine consumption and any medication they are receiving. Subjects will then undergo a through neurological assessment and blood pressure supine and standing, pulse rates, weight, height will be obtained.

A blood sample (15 cc) will be drawn to test the association to metabolic, hormonal and inflammatory mediators known to affect sleep (specifically: iron stores, thyroid function, and hemoglobin). Subjects will also undergo several performance based assessments and questionnaires on sleep and behavior.

All subjects will then be scheduled for a sleep polysomnography (PSG). Subjects will be invited to the sleep lab at TLVMC and asked to arrive at 9 pm and will be instructed on all procedures. Several body functions will be recorded during the PSG including brain activity, eye movement, oxygen and carbon dioxide blood levels, heart rate and rhythm, breathing rate and rhythm, the flow of air through the mouth and nose, body muscle movements, and chest and belly movement. The standard PSG will be fitted first and then the Xtrode system will be placed on the subject's face and the Axivity sensor will be placed on the subjects back (L4-5) using medical tape. This process should take approximately 45 minutes. After the systems are turned on, the subjects will be left in the quite room for a night sleep. The session will be video-taped to enable a comparison of movement with the wearable systems. The PSG and Xtrodes systems will be removed no later than 8 am the next morning.

Subjects will then be instructed on how to use the sleep "tattoo" at home. The system provided will include the controller, seven skin adhesives and a smartphone app, which will be used to obtain the data collected. Data is automatically transferred from the skin tattoo directly to the smartphone via a Bluetooth connection. The Axivity device which was placed on the lower back of the subjects will remain in place for the remaining 7 days. The device is waterproof thus there is no need for the subjects to don or doff the device until the end of the collection period. After the study, the systems will be returned to the medical centers for data transfer and analysis via carrier.

03

Conditions studied

  • Parkinson Disease
  • GBA Gene Mutation
  • Leucine-rich Repeat Kinase 2 (LRRK2) Gene Mutation

Browse trials for

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of PD (according to UK brain bank or Gelb criteria)
  • Hohen and Yahr stages I-IV
  • Age between 50-80
  • First-degree healthy relatives, carriers of mutations in the LRRK2 and GBA genes
  • Healthy volunteers
  • Healthy subjects with confirmed RBD
  • For patients with PD: only if they have a care partner at home who will be able to assist with the application of the technology
  • Willing and able to sign an

Exclusion criteria

Exclusion Criteria:

  • Any neurological condition other than PD (e.g. Stroke, MSA, parkinsonism)
  • Severe cognitive impairment (\<24)
  • Psychiatric disorders
  • Low back pain or any orthopaedic problem or pain that will prevent the subject from sleeping in the sleep lab or wearing the wearable sensors
  • For men: a beard (because of the tattoo adhesion
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Xtrodes home PSG system

    Wireless wearable system incorporates EEG, electrooculography (EOG) and EMG recordings over multiple nights in the home environment. The electrodes are printed on a thin sticker. These printed electrodes are marked by their conformity with the skin, light weight, ease of placement on the skin, and user comfort. The sleep-specific electrode array includes two surface EMG (electrodes 1 and 2), two EOG (electrodes 3 and 4) and four forehead EEG electrodes (electrodes 5-8) .

    Device: Xtrodes home PSG system

Interventions

  • DeviceXtrodes home PSG system

    Wireless, convenient and relies on actual recording of EMG, EOG and EEG in a home setting

    Also known as: Home PSG system

06

What researchers measure

Primary outcomes

  1. Changes in sleep architecture

    Frequency of RBD and severity of sleep interruptions

    Time frame: From placing the system to disassembling, up to 1 week

Secondary outcomes

  1. MDS-UPDRS

    MDS-UPDRS part III will be used to assess the relationship between sleep disorders and motor disability

    Time frame: Immediate after disassembling the system (day 7)

  2. REM Sleep Behavior Disorder Screening Questionnaire

    Patient self-rating instrument assessing the subject's sleep behavior with short questions that have to be answered by either "yes" or "no".

    Time frame: Immediate after disassembling the system (day 7)

  3. The Non-Motor Scale

    The Non-Motor Scale validated and commonly used 30-point questionnaire recognizes the non-motor difficulties often occur in PD. Areas covered include sleep, constipation, vision, smell, sexual problems and memory.

    Time frame: Immediate after disassembling the system (day 7)

  4. Geriatric Depression Scale

    The Geriatric Depression Scale is a self report assessment used to identify depression in the elderly. The questionnaire consists of 15 yes/no questions; one point is assigned to each answer. Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.

    Time frame: Immediate after disassembling the system (day 7)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Dec 2023, 42 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 42 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2020
First posted
May 14, 2020
StartActual
Jun 1, 2020
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2024
Last update
Mar 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04387812
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
May 14, 2020
Start date
Jun 1, 2020
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Mar 10, 2023

Study contacts

Anat Mirelman, PhD
Contact
anatmi@tlvmc.gov.il
97236973960
Liat Yahimovich
Contact
Liatya@tlvmc.gov.il
97236973960
Anat Mirelman, PhD
principal investigator · Laboratory of Early Markers of Neurodegeneration (LEMON), TASMC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion